Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for renal outcomes and mortality in diabetic kidney disease

Eur J Intern Med. 2021 Mar:85:127-129. doi: 10.1016/j.ejim.2020.11.017. Epub 2020 Nov 26.

Authors

Shimin Jiang¹, Jinying Fang², Tianyu Yu³, Wenge Li⁴

Affiliations

¹ Department of Nephrology, China-Japan Friendship Hospital, Beijing, China.
² Beijing University of Chinese Medicine, Beijing, China.
³ Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
⁴ Department of Nephrology, China-Japan Friendship Hospital, Beijing, China. Electronic address: wenge_lee2002@126.com.

PMID: 33250340
DOI: 10.1016/j.ejim.2020.11.017

No abstract available

Keywords: ACEIs; ARBs; Bayesian network meta-analysis; diabetic kidney disease; randomized controlled trials.

Publication types

Letter

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Diabetes Mellitus*
Diabetic Nephropathies* / drug therapy
Humans
Kidney Failure, Chronic*
Renin-Angiotensin System

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors